PMID- 34311471
OWN - NLM
STAT- MEDLINE
DCOM- 20220504
LR  - 20230202
IS  - 1098-8971 (Electronic)
IS  - 0272-8087 (Print)
IS  - 0272-8087 (Linking)
VI  - 42
IP  - 1
DP  - 2022 Feb
TI  - Role of Lipogenesis Rewiring in Hepatocellular Carcinoma.
PG  - 77-86
LID - 10.1055/s-0041-1731709 [doi]
AB  - Metabolic rewiring is one of the hallmarks of cancer. Altered de novo lipogenesis 
      is one of the pivotal metabolic events deregulated in cancers. Sterol regulatory 
      element-binding transcription factor 1 (SREBP1) controls the transcription of 
      major enzymes involved in de novo lipogenesis, including ACLY, ACACA, FASN, and 
      SCD. Studies have shown the increased de novo lipogenesis in human hepatocellular 
      carcinoma (HCC) samples. Multiple mechanisms, such as activation of the 
      AKT/mechanistic target of rapamycin (mTOR) pathway, lead to high SREBP1 induction 
      and the coordinated enhanced expression of ACLY, ACACA, FASN, and SCD genes. 
      Subsequent functional analyses have unraveled these enzymes' critical role(s) and 
      the related de novo lipogenesis in hepatocarcinogenesis. Importantly, targeting 
      these molecules might be a promising strategy for HCC treatment. This paper 
      comprehensively summarizes de novo lipogenesis rewiring in HCC and how this 
      pathway might be therapeutically targeted.
CI  - Thieme. All rights reserved.
FAU - Zhou, Yi
AU  - Zhou Y
AD  - Department of Infectious Diseases, The First Affiliated Hospital of Xi'an 
      Jiaotong University, Xi'an, China.
AD  - Department of Bioengineering and Therapeutic Sciences and Liver Center, 
      University of California, San Francisco, California.
FAU - Tao, Junyan
AU  - Tao J
AD  - Department of Pathology, University of Pittsburgh School of Medicine, University 
      of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
AD  - Pittsburgh Liver Research Center, University of Pittsburgh School of Medicine, 
      University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
FAU - Calvisi, Diego F
AU  - Calvisi DF
AD  - Institute of Pathology, University of Regensburg, Germany.
FAU - Chen, Xin
AU  - Chen X
AD  - Department of Bioengineering and Therapeutic Sciences and Liver Center, 
      University of California, San Francisco, California.
LA  - eng
GR  - P30 DK026743/DK/NIDDK NIH HHS/United States
GR  - R01 CA190606/CA/NCI NIH HHS/United States
GR  - R01 CA221916/CA/NCI NIH HHS/United States
GR  - R01 CA239251/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20210726
PL  - United States
TA  - Semin Liver Dis
JT  - Seminars in liver disease
JID - 8110297
SB  - IM
MH  - Carcinogenesis/genetics
MH  - *Carcinoma, Hepatocellular/pathology
MH  - Cell Line, Tumor
MH  - Humans
MH  - Lipogenesis/genetics
MH  - *Liver Neoplasms/pathology
PMC - PMC8789945
MID - NIHMS1745459
COIS- The authors declare no potential conflicts of interest.
EDAT- 2021/07/27 06:00
MHDA- 2022/05/06 06:00
PMCR- 2023/02/01
CRDT- 2021/07/26 20:30
PHST- 2021/07/27 06:00 [pubmed]
PHST- 2022/05/06 06:00 [medline]
PHST- 2021/07/26 20:30 [entrez]
PHST- 2023/02/01 00:00 [pmc-release]
AID - 10.1055/s-0041-1731709 [doi]
PST - ppublish
SO  - Semin Liver Dis. 2022 Feb;42(1):77-86. doi: 10.1055/s-0041-1731709. Epub 2021 Jul 
      26.